HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Effect of continuous administration of conjugated estrogen plus medroxyprogesterone acetate (Premelle) in postmenopausal women in Taiwan.
BACKGROUND To compare the metabolic effects on lipids and acceptability and safety of , and compliance with , a continuous administration of conjugated estrogen plus medroxyprogesterone acetate ( Premelle ) versus a placebo in non-hysterectomized postmenopausal women . METHODS Sixty-six generally healthy , female , early post-menopausal women , from 45 - 60 years of age , were r and omized for an administration of conjugated estrogen plus medroxyprogesterone acetate ( Premelle , Premarin 0.625 mg plus medroxyprogesterone acetate 2.5 mg/tablet orally ) or a placebo for 6 months . The changes in each patient 's lipid profiles from baseline , the frequency of hot flushes , bleeding occurrences , and climacteric symptoms , were evaluated . Safety was monitored by means of physical examination , Papanicolau smear , transvaginal ultrasonography , and laboratory check-up . Adverse events were also recorded . RESULTS The difference before and after treatment in serum LDL-C and total cholesterol ( TC ) was statistically significant in the Premelle group ( LDL-C , p = 0.006 , TC , p = 0.040 ) . No statistically significant difference in the change from baseline was observed in the levels of LDL-C and TC in the placebo treatment group . There was a statistically significant change from baseline in menopausal symptoms , which were evaluated by the Greene Climacteric Scales in the Premelle group . There was no clinical ly significant finding in the physical examination , vital signs , laboratory data , or endometrial thickness in either treatment group . The difference in the number of patients who reported an adverse event was not statistically significant between the 2 treatment groups . CONCLUSIONS This study demonstrated that Premelle was effective in decreasing LDL-C and total cholesterol levels , and also showed an improvement in some menopausal symptoms , such as vasomotor and sexual dysfunction symptoms . No significant bleeding was observed with Premelle , which was well tolerated in this study . The results of this study could support the use of Premelle tablets as a convenient alternative hormone therapy
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .